165 related articles for article (PubMed ID: 12323401)
1. Sequence changes in the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum antiviral cidofovir.
Kinchington PR; Araullo-Cruz T; Vergnes JP; Yates K; Gordon YJ
Antiviral Res; 2002 Oct; 56(1):73-84. PubMed ID: 12323401
[TBL] [Abstract][Full Text] [Related]
2. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand White rabbit ocular model.
Romanowski EG; Gordon YJ; Araullo-Cruz T; Yates KA; Kinchington PR
Invest Ophthalmol Vis Sci; 2001 Jul; 42(8):1812-5. PubMed ID: 11431446
[TBL] [Abstract][Full Text] [Related]
3. Cidofovir Diphosphate Inhibits Adenovirus 5 DNA Polymerase via both Nonobligate Chain Termination and Direct Inhibition, and Polymerase Mutations Confer Cidofovir Resistance on Intact Virus.
Chamberlain JM; Sortino K; Sethna P; Bae A; Lanier R; Bambara RA; Dewhurst S
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397065
[TBL] [Abstract][Full Text] [Related]
4. Isolation of human adenovirus type 5 variants resistant to the antiviral cidofovir.
Gordon YJ; Araullo-Cruz TP; Johnson YF; Romanowski EG; Kinchington PR
Invest Ophthalmol Vis Sci; 1996 Dec; 37(13):2774-8. PubMed ID: 8977495
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype.
Kornbluth RS; Smee DF; Sidwell RW; Snarsky V; Evans DH; Hostetler KY
Antimicrob Agents Chemother; 2006 Dec; 50(12):4038-43. PubMed ID: 16982794
[TBL] [Abstract][Full Text] [Related]
6. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture.
Cihlar T; Fuller MD; Mulato AS; Cherrington JM
Virology; 1998 Sep; 248(2):382-93. PubMed ID: 9721246
[TBL] [Abstract][Full Text] [Related]
7. Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.
James SH; Price NB; Hartline CB; Lanier ER; Prichard MN
Antimicrob Agents Chemother; 2013 Jul; 57(7):3321-5. PubMed ID: 23650158
[TBL] [Abstract][Full Text] [Related]
8. Isolation and characterization of cidofovir resistant vaccinia viruses.
Becker MN; Obraztsova M; Kern ER; Quenelle DC; Keith KA; Prichard MN; Luo M; Moyer RW
Virol J; 2008 May; 5():58. PubMed ID: 18479513
[TBL] [Abstract][Full Text] [Related]
9. Topical corticosteroids reverse the antiviral effect of topical cidofovir in the Ad5-inoculated New Zealand rabbit ocular model.
Romanowski EG; Araullo-Cruz T; Gordon YJ
Invest Ophthalmol Vis Sci; 1997 Jan; 38(1):253-7. PubMed ID: 9019458
[TBL] [Abstract][Full Text] [Related]
10. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model.
Romanowski EG; Yates KA; Gordon YJ
Antiviral Res; 2001 Dec; 52(3):275-80. PubMed ID: 11675144
[TBL] [Abstract][Full Text] [Related]
11. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation.
Xiong X; Smith JL; Chen MS
Antimicrob Agents Chemother; 1997 Mar; 41(3):594-9. PubMed ID: 9055999
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a cidofovir-resistant HHV-6 mutant obtained by in vitro selection.
Bonnafous P; Boutolleau D; Naesens L; Deback C; Gautheret-Dejean A; Agut H
Antiviral Res; 2008 Mar; 77(3):237-40. PubMed ID: 18241936
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model.
Romanowski EG; Gordon YJ
Invest Ophthalmol Vis Sci; 2000 Feb; 41(2):460-3. PubMed ID: 10670476
[TBL] [Abstract][Full Text] [Related]
14. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir.
Kern ER; Hartline C; Harden E; Keith K; Rodriguez N; Beadle JR; Hostetler KY
Antimicrob Agents Chemother; 2002 Apr; 46(4):991-5. PubMed ID: 11897580
[TBL] [Abstract][Full Text] [Related]
15. Murine cytomegalovirus resistant to antivirals has genetic correlates with human cytomegalovirus.
Scott GM; Ng HL; Morton CJ; Parker MW; Rawlinson WD
J Gen Virol; 2005 Aug; 86(Pt 8):2141-2151. PubMed ID: 16033961
[TBL] [Abstract][Full Text] [Related]
16. The 3'-to-5' exonuclease activity of vaccinia virus DNA polymerase is essential and plays a role in promoting virus genetic recombination.
Gammon DB; Evans DH
J Virol; 2009 May; 83(9):4236-50. PubMed ID: 19224992
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model.
de Oliveira CB; Stevenson D; LaBree L; McDonnell PJ; Trousdale MD
Antiviral Res; 1996 Jul; 31(3):165-72. PubMed ID: 8811201
[TBL] [Abstract][Full Text] [Related]
18. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase.
Xiong X; Smith JL; Kim C; Huang ES; Chen MS
Biochem Pharmacol; 1996 Jun; 51(11):1563-7. PubMed ID: 8630098
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
Scott GM; Weinberg A; Rawlinson WD; Chou S
Antimicrob Agents Chemother; 2007 Jan; 51(1):89-94. PubMed ID: 17043128
[TBL] [Abstract][Full Text] [Related]
20. Biochemical basis for increased susceptibility to Cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity.
Mendel DB; Barkhimer DB; Chen MS
Antimicrob Agents Chemother; 1995 Sep; 39(9):2120-2. PubMed ID: 8540727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
